

Francesco Silvestris

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5055242/publications.pdf>

Version: 2024-02-01

175
papers

6,273
citations

87401

40
h-index

100535

70
g-index

178
all docs

178
docs citations

178
times ranked

10824
citing authors

#	ARTICLE	IF	CITATIONS
1	Correlation between targeted RNAseq signature of breast cancer CTCs and onset of bone-only metastases. <i>British Journal of Cancer</i> , 2022, 126, 419-429.	2.9	10
2	Bone Metastases in Neuroendocrine Tumors: Molecular Pathogenesis and Implications in Clinical Practice. <i>Neuroendocrinology</i> , 2021, 111, 207-216.	1.2	13
3	Susceptibility to ischaemic heart disease: Focusing on genetic variants for ATP-sensitive potassium channel beyond traditional risk factors. <i>European Journal of Preventive Cardiology</i> , 2021, 28, 1495-1500.	0.8	22
4	The Impairment in Kidney Function in the Oral Anticoagulation Era. A Pathophysiological Insight. <i>Cardiovascular Drugs and Therapy</i> , 2021, 35, 505-519.	1.3	14
5	TOP2A expression predicts responsiveness to carfilzomib in myeloma and informs novel combinatorial strategies for enhanced proteasome inhibitor cell killing. <i>Leukemia and Lymphoma</i> , 2021, 62, 337-347.	0.6	2
6	Application of "omics" sciences to the prediction of bone metastases from breast cancer: State of the art. <i>Journal of Bone Oncology</i> , 2021, 26, 100337.	1.0	6
7	First prospective data on breast cancer patients from the multicentre italian bone metastasis database. <i>Scientific Reports</i> , 2021, 11, 4329.	1.6	8
8	Uterine carcinosarcoma: An overview. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 163, 103369.	2.0	16
9	A Lipidomic Approach to Identify Potential Biomarkers in Exosomes From Melanoma Cells With Different Metastatic Potential. <i>Frontiers in Physiology</i> , 2021, 12, 748895.	1.3	21
10	Extracellular Vesicles and Epigenetic Modifications Are Hallmarks of Melanoma Progression. <i>International Journal of Molecular Sciences</i> , 2020, 21, 52.	1.8	38
11	An Italian Retrospective Survey on Bone Metastasis in Melanoma: Impact of Immunotherapy and Radiotherapy on Survival. <i>Frontiers in Oncology</i> , 2020, 10, 1652.	1.3	10
12	Liquid Biopsy as a Tool Exploring in Real-Time Both Genomic Perturbation and Resistance to EGFR Antagonists in Colorectal Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 581130.	1.3	7
13	DEAD-Box Helicase 4 (Ddx4)+ Stem Cells Sustain Tumor Progression in Non-Serous Ovarian Cancers. <i>International Journal of Molecular Sciences</i> , 2020, 21, 6096.	1.8	2
14	Large Extracellular Vesicles "A New Frontier of Liquid Biopsy in Oncology. <i>International Journal of Molecular Sciences</i> , 2020, 21, 6543.	1.8	17
15	Pulmonary enteric adenocarcinoma: an overview. <i>Expert Reviews in Molecular Medicine</i> , 2020, 22, e1.	1.6	11
16	Dual-procedural separation of CTCs in cutaneous melanoma provides useful information for both molecular diagnosis and prognosis. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592090541.	1.4	10
17	Relationship of para- and perirenal fat and epicardial fat with metabolic parameters in overweight and obese subjects. <i>Eating and Weight Disorders</i> , 2019, 24, 67-72.	1.2	28
18	Tumor-derived exosomes promote the in vitro osteotropism of melanoma cells by activating the SDF-1/CXCR4/CXCR7 axis. <i>Journal of Translational Medicine</i> , 2019, 17, 230.	1.8	41

#	ARTICLE	IF	CITATIONS
19	The Role of Cytotoxic Chemotherapy in Well-Differentiated Gastroenteropancreatic and Lung Neuroendocrine Tumors. <i>Current Treatment Options in Oncology</i> , 2019, 20, 72.	1.3	7
20	Revisiting the Role of Exosomes in Colorectal Cancer: Where Are We Now?. <i>Frontiers in Oncology</i> , 2019, 9, 521.	1.3	35
21	The mechanisms of acute interstitial nephritis in the era of immune checkpoint inhibitors in melanoma. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591987554.	1.4	21
22	Cutaneous metastasis as a primary presentation of a pulmonary enteric adenocarcinoma. <i>International Journal of Biological Markers</i> , 2019, 34, 421-426.	0.7	8
23	The Tumor Microenvironment in Neuroendocrine Tumors: Biology and Therapeutic Implications. <i>Neuroendocrinology</i> , 2019, 109, 83-99.	1.2	87
24	The metabolic milieu in melanoma: Role of immune suppression by CD73/adenosine. <i>Tumor Biology</i> , 2019, 41, 101042831983713.	0.8	29
25	Rare Dihydropyrimidine Dehydrogenase Variants and Toxicity by Flurpyrimidines: A Case Report. <i>Frontiers in Oncology</i> , 2019, 9, 139.	1.3	10
26	25 Hydroxyvitamin D Levels are Negatively and Independently Associated with Fat Mass in a Cohort of Healthy Overweight and Obese Subjects. <i>Endocrine, Metabolic and Immune Disorders - Drug Targets</i> , 2019, 19, 838-844.	0.6	34
27	Dissection of major cancer gene variants in subsets of circulating tumor cells in advanced breast cancer. <i>Scientific Reports</i> , 2019, 9, 17276.	1.6	16
28	Immune System Evasion as Hallmark of Melanoma Progression: The Role of Dendritic Cells. <i>Frontiers in Oncology</i> , 2019, 9, 1148.	1.3	90
29	DAXX mutations as potential genomic markers of malignant evolution in small nonfunctioning pancreatic neuroendocrine tumors. <i>Scientific Reports</i> , 2019, 9, 18614.	1.6	26
30	Gene Fusion in NSCLC. , 2019, , 443-464.		1
31	Management of NETs in the Precision Medicine Era. , 2019, , 575-589.		0
32	Metastatic bone disease: Pathogenesis and therapeutic options. <i>Journal of Bone Oncology</i> , 2019, 15, 100205.	1.0	153
33	Circulating tumour cells and their association with bone metastases in patients with neuroendocrine tumours. <i>British Journal of Cancer</i> , 2019, 120, 294-300.	2.9	25
34	Local treatment for focal progression in metastatic neuroendocrine tumors. <i>Endocrine-Related Cancer</i> , 2019, 26, 405-409.	1.6	10
35	In vitro differentiation of human oocyte-like cells from oogonial stem cells: single-cell isolation and molecular characterization. <i>Human Reproduction</i> , 2018, 33, 464-473.	0.4	90
36	The management of refractory carcinoid syndrome: challenges and opportunities ahead. <i>Journal of Medical Economics</i> , 2018, 21, 241-243.	1.0	1

#	ARTICLE	IF	CITATIONS
37	Serum exosomes as predictors of clinical response to ipilimumab in metastatic melanoma. <i>Oncotarget</i> , 2018, 7, e1387706.	2.1	76
38	SNPs in predicting clinical efficacy and toxicity of chemotherapy: walking through the quicksand. <i>Oncotarget</i> , 2018, 9, 25355-25382.	0.8	34
39	Exosomes in melanoma: a role in tumor progression, metastasis and impaired immune system activity. <i>Oncotarget</i> , 2018, 9, 20826-20837.	0.8	97
40	Liquid biopsy of cancer: a multimodal diagnostic tool in clinical oncology. <i>Therapeutic Advances in Medical Oncology</i> , 2018, 10, 175883591879463.	1.4	317
41	Animal-type melanoma: dog or wolf? A review of the literature and a case report. <i>Expert Reviews in Molecular Medicine</i> , 2018, 20, e5.	1.6	2
42	Vitamin D in melanoma: Controversies and potential role in combination with immune check-point inhibitors. <i>Cancer Treatment Reviews</i> , 2018, 69, 21-28.	3.4	31
43	Double Heterozygosity for BRCA1 Pathogenic Variant and BRCA2 Polymorphic Stop Codon K3326X: A Case Report in a Southern Italian Family. <i>International Journal of Molecular Sciences</i> , 2018, 19, 285.	1.8	14
44	Uric Acid, Metabolic Syndrome and Atherosclerosis: The Chicken or the Egg, Which Comes First?. <i>Endocrine, Metabolic and Immune Disorders - Drug Targets</i> , 2018, 18, 251-259.	0.6	18
45	Low 25 Hydroxyvitamin D Levels are Independently Associated with Autoimmune Thyroiditis in a Cohort of Apparently Healthy Overweight and Obese Subjects. <i>Endocrine, Metabolic and Immune Disorders - Drug Targets</i> , 2018, 18, 646-652.	0.6	22
46	Everolimus restrains the IL-17A-dependent osteoclast-like transdifferentiation of dendritic cells in multiple myeloma. <i>Experimental Hematology</i> , 2017, 47, 48-53.	0.2	3
47	<i>ALK</i> gene alterations in cancer: biological aspects and therapeutic implications. <i>Pharmacogenomics</i> , 2017, 18, 277-292.	0.6	8
48	Adverse drug reactions after intravenous rituximab infusion are more common in hematologic malignancies than in autoimmune disorders and can be predicted by the combination of few clinical and laboratory parameters: results from a retrospective, multicenter study of 374 patients. <i>Leukemia and Lymphoma</i> , 2017, 58, 2633-2641.	0.6	19
49	Immune-related adverse events during anticancer immunotherapy: Pathogenesis and management (Review). <i>Oncology Letters</i> , 2017, 14, 5671-5680.	0.8	54
50	1,25(OH) ₂ vitamin D(3) contributes to osteoclast-like trans-differentiation of malignant plasma cells. <i>Experimental Cell Research</i> , 2017, 358, 260-268.	1.2	11
51	Ovarian cancer: Novel molecular aspects for clinical assessment. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 117, 12-29.	2.0	25
52	Characterization of a Rare Nonpathogenic Methylenetetrahydrofolatereductase (MTHFR) Gene Mutation p.Lys215del in a Southern Italian family. <i>Human Mutation</i> , 2017, 38, 120-121.	1.1	2
53	Characterization of a Rare Nonpathogenic Sequence Variant (c.1905C>T) of the Dihydropyrimidine Dehydrogenase Gene (DPYD). <i>International Journal of Biological Markers</i> , 2017, 32, 357-360.	0.7	3
54	Immune Profile of Obese People and In Vitro Effects of Red Grape Polyphenols on Peripheral Blood Mononuclear Cells. <i>Oxidative Medicine and Cellular Longevity</i> , 2017, 2017, 1-11.	1.9	20

#	ARTICLE	IF	CITATIONS
55	pIL6-TRAIL-engineered umbilical cord mesenchymal/stromal stem cells are highly cytotoxic for myeloma cells both in vitro and in vivo. <i>Stem Cell Research and Therapy</i> , 2017, 8, 206.	2.4	25
56	Immune system and melanoma biology: a balance between immunosurveillance and immune escape. <i>Oncotarget</i> , 2017, 8, 106132-106142.	0.8	174
57	Osteotropism of neuroendocrine tumors: role of the CXCL12/CXCR4 pathway in promoting EMT in vitro. <i>Oncotarget</i> , 2017, 8, 22534-22549.	0.8	21
58	Independent Relationship of Osteocalcin Circulating Levels with Obesity, Type 2 Diabetes, Hypertension, and HDL Cholesterol. <i>Endocrine, Metabolic and Immune Disorders - Drug Targets</i> , 2017, 16, 270-275.	0.6	12
59	Independent Relationship between Serum Osteocalcin and Uric Acid in a Cohort of Apparently Healthy Obese Subjects. <i>Endocrine, Metabolic and Immune Disorders - Drug Targets</i> , 2017, 17, 207-212.	0.6	7
60	Desmoid Tumors in Familial Adenomatous Polyposis. <i>Anticancer Research</i> , 2017, 37, 3357-3366.	0.5	62
61	Next-generation Sequencing (NGS) Analysis on Single Circulating Tumor Cells (CTCs) with No Need of Whole-genome Amplification (WGA). <i>Cancer Genomics and Proteomics</i> , 2017, 14, 173-179.	1.0	29
62	Sirtuins and Cancer: Role in the Epithelial-Mesenchymal Transition. <i>Oxidative Medicine and Cellular Longevity</i> , 2016, 2016, 1-9.	1.9	62
63	Safety and efficacy of lenalidomide in combination with rituximab in recurrent indolent non-follicular lymphoma: final results of a phase II study conducted by the Fondazione Italiana Linfomi. <i>Haematologica</i> , 2016, 101, e196-e199.	1.7	15
64	Mediterranean Diet and cancer risk: an open issue. <i>International Journal of Food Sciences and Nutrition</i> , 2016, 67, 593-605.	1.3	29
65	Cilengitide restrains the osteoclast-like bone resorbing activity of myeloma plasma cells. <i>British Journal of Haematology</i> , 2016, 173, 59-69.	1.2	10
66	Reviewing the Osteotropism in Neuroendocrine Tumors: The Role of Epithelial-Mesenchymal Transition. <i>Neuroendocrinology</i> , 2016, 103, 321-334.	1.2	19
67	Parallelism of DOG1 expression with recurrence risk in gastrointestinal stromal tumors bearing KIT or PDGFRA mutations. <i>BMC Cancer</i> , 2016, 16, 87.	1.1	20
68	Obesity and Breast Cancer: Molecular Interconnections and Potential Clinical Applications. <i>Oncologist</i> , 2016, 21, 404-417.	1.9	83
69	miRNAs in melanoma: a defined role in tumor progression and metastasis. <i>Expert Review of Clinical Immunology</i> , 2016, 12, 79-89.	1.3	40
70	NETs: organ-related epigenetic derangements and potential clinical applications. <i>Oncotarget</i> , 2016, 7, 57414-57429.	0.8	23
71	Para- and perirenal ultrasonographic fat thickness is associated with 24-hours mean diastolic blood pressure levels in overweight and obese subjects. <i>BMC Cardiovascular Disorders</i> , 2015, 15, 108.	0.7	52
72	Everolimus restrains the paracrine pro-osteoclast activity of breast cancer cells. <i>BMC Cancer</i> , 2015, 15, 692.	1.1	16

#	ARTICLE	IF	CITATIONS
73	Erdheim-Chester disease: A systematic review. <i>Critical Reviews in Oncology/Hematology</i> , 2015, 95, 1-11.	2.0	153
74	Dendritic cell-derived exosomes (Dex) are potential biomarkers of response to Ipilimumab in metastatic melanoma. <i>Journal of Translational Medicine</i> , 2015, 13, .	1.8	2
75	Paraneoplastic Focal Segmental Glomerulosclerosis in Sarcomatoid Renal Cell Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, e66-e70.	0.8	5
76	A Peculiar Molecular Profile of Umbilical Cord-Mesenchymal Stromal Cells Drives Their Inhibitory Effects on Multiple Myeloma Cell Growth and Tumor Progression. <i>Stem Cells and Development</i> , 2015, 24, 1457-1470.	1.1	21
77	Circulating dendritic cell levels identify high-risk stage II-III melanoma patients: a potential role as additional prognostic marker. <i>Journal of Translational Medicine</i> , 2015, 13, .	1.8	0
78	Avβ3 integrin: Pathogenetic role in osteotropic tumors. <i>Critical Reviews in Oncology/Hematology</i> , 2015, 96, 183-193.	2.0	38
79	Targeted Therapies for Bone Metastases. <i>Current Clinical Pathology</i> , 2015, , 249-266.	0.0	0
80	Natural History of Malignant Bone Disease in Hepatocellular Carcinoma: Final Results of a Multicenter Bone Metastasis Survey. <i>PLoS ONE</i> , 2014, 9, e105268.	1.1	33
81	New Insights Into the Molecular Pathogenesis of Langerhans Cell Histiocytosis. <i>Oncologist</i> , 2014, 19, 151-163.	1.9	47
82	The immune escape in melanoma: role of the impaired dendritic cell function. <i>Expert Review of Clinical Immunology</i> , 2014, 10, 1395-1404.	1.3	56
83	Does cilengitide deserve another chance?. <i>Lancet Oncology</i> , The, 2014, 15, e584-e585.	5.1	40
84	PTHrP Produced by Myeloma Plasma Cells Regulates Their Survival and Pro-Osteoclast Activity For Bone Disease Progression. <i>Journal of Bone and Mineral Research</i> , 2014, 29, 55-66.	3.1	53
85	Bone metastases in hepatocellular carcinoma: an emerging issue. <i>Cancer and Metastasis Reviews</i> , 2014, 33, 333-342.	2.7	38
86	Targeting bone metastatic cancer: Role of the mTOR pathway. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2014, 1845, 248-254.	3.3	25
87	An imbalance between Beclin-1 and p62 expression promotes the proliferation of myeloma cells through autophagy regulation. <i>Experimental Hematology</i> , 2014, 42, 897-908.e1.	0.2	13
88	Molecular target therapy for bone metastasis: starting a new era with denosumab, a RANKL inhibitor. <i>Expert Opinion on Biological Therapy</i> , 2014, 14, 15-26.	1.4	17
89	Possible Direct Influence of Complement 3 in Decreasing Insulin Sensitivity in a Cohort of Overweight and Obese Subjects. <i>Endocrine, Metabolic and Immune Disorders - Drug Targets</i> , 2014, 13, 301-305.	0.6	4
90	Immature dendritic cells in multiple myeloma are prone to osteoclast-like differentiation through interleukin-17 stimulation. <i>British Journal of Haematology</i> , 2013, 161, 821-831.	1.2	42

#	ARTICLE	IF	CITATIONS
91	Bendamustine overcomes resistance to melphalan in myeloma cell lines by inducing cell death through mitotic catastrophe. <i>Cellular Signalling</i> , 2013, 25, 1108-1117.	1.7	21
92	Cytherapies in multiple myeloma: a complementary approach to current treatments?. <i>Expert Opinion on Biological Therapy</i> , 2013, 13, S23-S34.	1.4	4
93	Novel lenalidomide-based combinations for treatment of multiple myeloma. <i>Critical Reviews in Oncology/Hematology</i> , 2013, 85, 9-20.	2.0	11
94	Possible Role of Hyperinsulinemia and Insulin Resistance in Lower Vitamin D Levels in Overweight and Obese Patients. <i>BioMed Research International</i> , 2013, 2013, 1-6.	0.9	28
95	Obesity and Heart Failure. <i>Endocrine, Metabolic and Immune Disorders - Drug Targets</i> , 2013, 13, 51-57.	0.6	36
96	Obesity as a Major Risk Factor for Cancer. <i>Journal of Obesity</i> , 2013, 2013, 1-11.	1.1	669
97	Final Results Of a Phase II Study Of Lenalidomide In Combination With Rituximab For The Treatment Of Indolent Non Follicular Non Hodgkin Lymphoma. <i>Blood</i> , 2013, 122, 4383-4383.	0.6	1
98	Cell Fusion in Myeloma Marrow Microenvironment: Role in Tumor Progression. <i>Critical Reviews in Oncogenesis</i> , 2013, 18, 75-95.	0.2	2
99	Therapeutic approaches to myeloma bone disease: An evolving story. <i>Cancer Treatment Reviews</i> , 2012, 38, 787-797.	3.4	25
100	Abdominal Obesity Is Characterized by Higher Pulse Pressure: Possible Role of Free Triiodothyronine. <i>Journal of Obesity</i> , 2012, 2012, 1-5.	1.1	10
101	Lenalidomide in multiple myeloma: current experimental and clinical data. <i>European Journal of Haematology</i> , 2012, 88, 279-291.	1.1	14
102	In vitro anti-myeloma activity of TRAIL-expressing adipose-derived mesenchymal stem cells. <i>British Journal of Haematology</i> , 2012, 157, 586-598.	1.2	46
103	Results of a Phase II Study of Lenalidomide in Combination with Rituximab for the Treatment of Indolent Non Follicular Non Hodgkin Lymphoma (NHL). <i>Blood</i> , 2012, 120, 1645-1645.	0.6	1
104	Dendritic Cells and Malignant Plasma Cells: An Alliance in Multiple Myeloma Tumor Progression?. <i>Oncologist</i> , 2011, 16, 1040-1048.	1.9	38
105	Arterial hypertension in obesity: relationships with hormone and anthropometric parameters. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2011, 18, 240-247.	3.1	14
106	Immature dendritic cells from patients with multiple myeloma are prone to osteoclast differentiation in vitro. <i>Experimental Hematology</i> , 2011, 39, 773-783.e1.	0.2	33
107	Mesenchymal Stem Cells: A New Promise in Anticancer Therapy. <i>Stem Cells and Development</i> , 2011, 20, 1-10.	1.1	47
108	Relationship between C3 Levels and Common Carotid Intima-Media Thickness in Overweight and Obese Patients. <i>Obesity Facts</i> , 2011, 4, 159-163.	1.6	11

#	ARTICLE	IF	CITATIONS
109	Urokinase Receptor (uPAR) Ligand based Recombinant Toxins for Human Cancer Therapy. <i>Current Pharmaceutical Design</i> , 2011, 17, 1979-1983.	0.9	6
110	Cell Fusion and Hyperactive Osteoclastogenesis in Multiple Myeloma. <i>Advances in Experimental Medicine and Biology</i> , 2011, 714, 113-128.	0.8	15
111	Constitutive down-regulation of Osterix in osteoblasts from myeloma patients: In vitro effect of Bortezomib and Lenalidomide. <i>Leukemia Research</i> , 2010, 34, 243-249.	0.4	27
112	Cytokine Overproduction, T-Cell Activation, and Defective T-Regulatory Functions Promote Nephritis in Systemic Lupus Erythematosus. <i>Journal of Biomedicine and Biotechnology</i> , 2010, 2010, 1-6.	3.0	51
113	Targeted Therapies in Cancer. <i>BioDrugs</i> , 2010, 24, 77-88.	2.2	36
114	Umbilical Cord Mesenchymal Stem Cells: Role of Regulatory Genes in Their Differentiation to Osteoblasts. <i>Stem Cells and Development</i> , 2009, 18, 1211-1220.	1.1	41
115	Bone-Resorbing Cells in Multiple Myeloma: Osteoclasts, Myeloma Cell Polykaryons, or Both?. <i>Oncologist</i> , 2009, 14, 264-275.	1.9	26
116	Oversecretion of Cytokines and Chemokines in Lupus Nephritis Is Regulated by Intraparenchymal Dendritic Cells. <i>Annals of the New York Academy of Sciences</i> , 2009, 1173, 449-457.	1.8	29
117	β 3 Integrin Subunit Mediates the Bone-Resorbing Function Exerted by Cultured Myeloma Plasma Cells. <i>Cancer Research</i> , 2009, 69, 6738-6746.	0.4	32
118	Functional expression of the calcitonin receptor by human T and B cells. <i>Human Immunology</i> , 2009, 70, 678-685.	1.2	9
119	Role of Active Drug Transporters in Refractory Multiple Myeloma. <i>Current Topics in Medicinal Chemistry</i> , 2009, 9, 218-224.	1.0	18
120	Glomerular accumulation of plasmacytoid dendritic cells in active lupus nephritis: Role of interleukin-18. <i>Arthritis and Rheumatism</i> , 2008, 58, 251-262.	6.7	207
121	Expression and function of the calcitonin receptor by myeloma cells in their osteoclast-like activity in vitro. <i>Leukemia Research</i> , 2008, 32, 611-623.	0.4	23
122	Overexpression of interleukin-12 and T helper 1 predominance in lupus nephritis. <i>Clinical and Experimental Immunology</i> , 2008, 154, 247-254.	1.1	97
123	Negative Regulation of the Osteoblast Function in Multiple Myeloma through the Repressor Gene E4BP4 Activated by Malignant Plasma Cells. <i>Clinical Cancer Research</i> , 2008, 14, 6081-6091.	3.2	32
124	Myeloma bone disease: Pathogenetic mechanisms and clinical assessment. <i>Leukemia Research</i> , 2007, 31, 129-138.	0.4	44
125	Increased IL-18 Production by Dendritic Cells in Active Inflammatory Myopathies. <i>Annals of the New York Academy of Sciences</i> , 2007, 1107, 184-192.	1.8	26
126	In-vitro functional phenotypes of plasma cell lines from patients with multiple myeloma. <i>Leukemia and Lymphoma</i> , 2006, 47, 1921-1931.	0.6	11

#	ARTICLE	IF	CITATIONS
127	Deregulated expression of monocyte chemoattractant protein-1 (MCP-1) in arterial hypertension: role in endothelial inflammation and atheromasia. <i>Journal of Hypertension</i> , 2006, 24, 1307-1318.	0.3	41
128	Interleukin-18 overexpression as a hallmark of the activity of autoimmune inflammatory myopathies. <i>Clinical and Experimental Immunology</i> , 2006, 146, 21-31.	1.1	59
129	Antibody Production and In Vitro Behavior of CD27-Defined B-Cell Subsets: Persistent Hepatitis C Virus Infection Changes the Rules. <i>Journal of Virology</i> , 2006, 80, 3923-3934.	1.5	69
130	The Interplay of Chemokines and Dendritic Cells in the Pathogenesis of Lupus Nephritis. <i>Annals of the New York Academy of Sciences</i> , 2005, 1051, 421-432.	1.8	43
131	Functional osteoclast-like transformation of cultured human myeloma cell lines. <i>British Journal of Haematology</i> , 2005, 130, 926-938.	1.2	39
132	Th1 cytokines in the pathogenesis of lupus nephritis: The role of IL-18. <i>Autoimmunity Reviews</i> , 2005, 4, 542-548.	2.5	66
133	Statins activate the mitochondrial pathway of apoptosis in human lymphoblasts and myeloma cells. <i>Carcinogenesis</i> , 2005, 26, 883-891.	1.3	230
134	Impaired osteoblastogenesis in myeloma bone disease: role of upregulated apoptosis by cytokines and malignant plasma cells. <i>British Journal of Haematology</i> , 2004, 126, 475-486.	1.2	90
135	Osteoclast-like Cell Formation by Circulating Myeloma B Lymphocytes: Role of RANK-L. <i>Leukemia and Lymphoma</i> , 2004, 45, 377-380.	0.6	16
136	Recent Advances in Understanding the Pathogenesis of Anemia in Multiple Myeloma. <i>International Journal of Hematology</i> , 2003, 78, 121-125.	0.7	21
137	Upregulation of osteoblast apoptosis by malignant plasma cells: a role in myeloma bone disease. <i>British Journal of Haematology</i> , 2003, 122, 39-52.	1.2	65
138	Enhancement of T cell apoptosis correlates with increased serum levels of soluble Fas (CD95/Apo-I) in active lupus. <i>Lupus</i> , 2003, 12, 8-14.	0.8	31
139	Anemia in Multiple Myeloma: Role of Deregulated Plasma Cell Apoptosis. <i>Leukemia and Lymphoma</i> , 2002, 43, 1527-1533.	0.6	10
140	Negative regulation of erythroblast maturation by Fas-L+/TRAIL+ highly malignant plasma cells: a major pathogenetic mechanism of anemia in multiple myeloma. <i>Blood</i> , 2002, 99, 1305-1313.	0.6	97
141	Upregulation of erythroblast apoptosis by malignant plasma cells: a new pathogenetic mechanism of anemia in multiple myeloma. <i>Reviews in Clinical and Experimental Hematology</i> , 2002, Suppl 1, 39-46.	0.1	1
142	LFA-1 expression on CD4+CD45RO+ peripheral blood T-lymphocytes in RR MS: effects induced by rIFN γ -1a. <i>Journal of the Neurological Sciences</i> , 2001, 186, 65-73.	0.3	5
143	Fas-L up-regulation by highly malignant myeloma plasma cells: role in the pathogenesis of anemia and disease progression. <i>Blood</i> , 2001, 97, 1155-1164.	0.6	51
144	Anti-Fas (CD95/Apo-I) Autoantibodies and Soluble Fas Levels Concur in T Cell Depletion in HIV Type 1 Infection. <i>AIDS Research and Human Retroviruses</i> , 2001, 17, 603-614.	0.5	4

#	ARTICLE	IF	CITATIONS
145	Immunogenicity of an Eight Amino Acid Domain Shared by Fas (CD95/Apo-I) and HIV-1 gp120. I. Structural and Antigenic Analysis. <i>Molecular Medicine</i> , 2000, 6, 494-508.	1.9	4
146	VEINCTR-N, an Immunogenic Epitope of Fas (CD95/Apo-I), and Soluble Fas Enhance T-cell Apoptosis in vitro. II. Functional Analysis and Possible Implications in HIV-1 Disease. <i>Molecular Medicine</i> , 2000, 6, 509-526.	1.9	8
147	Nef protein induces differential effects in CD8+cells from HIV-1-infected patients. <i>European Journal of Clinical Investigation</i> , 1999, 29, 980-991.	1.7	5
148	Urinary loss of immunoglobulin G anti-F(ab ϵ) ₂ and anti-DNA antibody in systemic lupus erythematosus nephritis. <i>Translational Research</i> , 1998, 132, 210-222.	2.4	4
149	The effectiveness and tolerability of epoetin alfa in patients with multiple myeloma refractory to chemotherapy. <i>International Journal of Clinical and Laboratory Research</i> , 1998, 28, 127-134.	1.0	48
150	Functional Fas-ligand expression on T cells from HIV-1-infected patients is unrelated to CD4+ lymphopenia. <i>International Journal of Clinical and Laboratory Research</i> , 1998, 28, 215-225.	1.0	11
151	CD8+ /CD57+ cells and apoptosis suppress T-cell functions in multiple myeloma. <i>British Journal of Haematology</i> , 1998, 100, 469-477.	1.2	49
152	Fas/Fas ligand (FasL)-deregulated apoptosis and IL-6 insensitivity in highly malignant myeloma cells. <i>Clinical and Experimental Immunology</i> , 1998, 114, 179-188.	1.1	25
153	Cross-reactivity of human igg anti-F(ab ϵ) ₂ antibody with DNA and other nuclear antigens. <i>Arthritis and Rheumatism</i> , 1997, 40, 109-123.	6.7	12
154	Affinity columns containing anti-DNA Id+ human myeloma proteins adsorb human epibodies from intravenous gamma globulin. <i>Arthritis and Rheumatism</i> , 1997, 40, 683-693.	6.7	11
155	Overexpression of Fas antigen on T cells in advanced HIV-1 infection: differential ligation constantly induces apoptosis. <i>Aids</i> , 1996, 10, 131-141.	1.0	94
156	Shared V-Region Antigens and Cross-Reacting Specificities of Human IgG Anti-F(ab ϵ) ₂ and Anti-DNA Antibodies. <i>Clinical Immunology and Immunopathology</i> , 1996, 80, 194-203.	2.1	8
157	Cross-linking of Fas By Antibodies to a Peculiar Domain of gp120 V3 Loop Can Enhance T Cell Apoptosis in HIV-1â€infecte Patients. <i>Journal of Experimental Medicine</i> , 1996, 184, 2287-2300.	4.2	26
158	Immunomodulation of T and B cell functions in multiple myeloma patients treated with combined erythropoietin and Î±-interferon therapy. <i>International Journal of Clinical and Laboratory Research</i> , 1995, 25, 79-83.	1.0	9
159	Long-term therapy with recombinant human erythropoietin (rHu-EPO) in progressing multiple myeloma. <i>Annals of Hematology</i> , 1995, 70, 313-318.	0.8	51
160	Molecular localization of human IgG anti-F(ab ϵ) ₂ reactivity with variable- and constant-region Î± light-chain epitopes. <i>Journal of Clinical Immunology</i> , 1995, 15, 349-362.	2.0	3
161	Autoreactivity in HIV-1 Infection: The Role of Molecular Mimicry. <i>Clinical Immunology and Immunopathology</i> , 1995, 75, 197-205.	2.1	81
162	IgG Anti-F(ab ϵ) ₂ Antibodies from SLE Patients React with Immunodominant Residues in Î± CDRs, but Show Reduced CÎ± Region Reactivity. <i>Clinical Immunology and Immunopathology</i> , 1995, 77, 366-373.	2.1	0

#	ARTICLE	IF	CITATIONS
163	Expression of F4, 8.12, 3I, and 16/6 Anti-DNA Idiotype-Related Antigens on Cationic Human IgG Myeloma Proteins. <i>Clinical Immunology and Immunopathology</i> , 1994, 73, 215-223.	2.1	3
164	Distribution and Antigenic Analysis of Circulating F(ab ϵ) ₂ -Reactive IgG in Patients with HIV-1 Infection. <i>Clinical Immunology and Immunopathology</i> , 1994, 73, 229-234.	2.1	4
165	Molecular Specificities of CD4+ T Cell-Reactive IgM in Human Immunodeficiency Virus (HIV-1) Infection. <i>Clinical Immunology and Immunopathology</i> , 1994, 70, 40-46.	2.1	7
166	Human anti-F(ab ϵ) ₂ antibodies show preferential reactivity for F(ab ϵ) ₂ molecules bearing λ light chains. <i>Clinical Immunology and Immunopathology</i> , 1992, 65, 176-182.	2.1	2
167	Differential isotype expression and binding properties of T cell-reactive antibodies in human immunodeficiency virus (HIV) infection. <i>Journal of Clinical Immunology</i> , 1992, 12, 107-115.	2.0	2
168	Parallelism of serum anti-F(ab ϵ) ₂ and anti-cationic IgG reactivities in patients with systemic lupus erythematosus. <i>Clinical Immunology and Immunopathology</i> , 1991, 59, 256-270.	2.1	4
169	Monoclonal antibodies against human anti-F(ab ϵ) ₂ antibodies react with light chain epitopes. <i>Clinical Immunology and Immunopathology</i> , 1991, 59, 139-155.	2.1	4
170	Distribution of anti-F(ab ϵ) ₂ antibodies and the 16/6 idiotype in systemic lupus erythematosus (SLE) probands and kindreds. <i>Journal of Clinical Immunology</i> , 1989, 9, 462-468.	2.0	5
171	Isotype, distribution and target analysis of lymphocyte reactive antibodies in patients with human immunodeficiency virus infection. <i>Clinical Immunology and Immunopathology</i> , 1989, 53, 329-340.	2.1	10
172	In vitro inhibition of anti-DNA producing cells from systemic lupus erythematosus patients by autologous anti-F(ab ϵ) ₂ antibodies. <i>Clinical Immunology and Immunopathology</i> , 1987, 42, 50-62.	2.1	17
173	Discrepancy in the expression of autoantibodies in healthy aged individuals. <i>Clinical Immunology and Immunopathology</i> , 1985, 35, 234-244.	2.1	35
174	Studies of anti-f(ab') ₂ antibodies and possible immunologic control mechanisms in systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 1984, 27, 1387-1396.	6.7	80
175	New clinical and immunological trends in cryoglobulinemia. <i>Research in Clinic and Laboratory</i> , 1980, 10, 51-57.	0.3	11